

## Supplementary Materials

### **Circular RNA hsa-circ-0001030 suppresses proliferation and cisplatin tolerance in TSCC via interaction with PKM2**

**Haojie Yang<sup>1,2,#</sup>, Yingzhe Yan<sup>1,2,#</sup>, Zicong Tan<sup>1,2,#</sup>, Xiaoying Xu<sup>1,2</sup>, Kang Chen<sup>1,2</sup>, Qin Li<sup>2,3</sup>, Ning Liufu<sup>1,2</sup>, Fengtao Ji<sup>1,2</sup>**

<sup>1</sup>Department of Anesthesia, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510000, Guangdong, China.

<sup>2</sup>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510000, Guangdong, China.

<sup>3</sup>Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510000, Guangdong, China.

<sup>#</sup>These authors contributed equally to this work and share first authorship.


**Correspondence to:** Prof. Fengtao Ji, Ning Liufu, Department of Anesthesia, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510000, Guangdong, China. E-mail: [jift@mail.sysu.edu.cn](mailto:jift@mail.sysu.edu.cn); [liufn3@mail.sysu.edu.cn](mailto:liufn3@mail.sysu.edu.cn)

**Supplementary Table 1. Primer sequence**


	<b>Forward Sequence (5'-3')</b>	<b>Reverse Sequence (5'-3')</b>
<b>ACTB</b>	CATGTACGTTGCTATCCAGGC	CTCCTTAATGTCACGCACGAT
<b>GAPDH</b>	TGCACCACCAACTGCTTAGC	GGCATGGACTGTGGTCATGAG
<b>Hsa-circ-0001030</b>	AGCAAAGTGAAGGGACCAGATG	GCTTCAGCTCTTCCATTGCT
<b>Hsa-circ-0000319</b>	CAATGTGGAAGGTCCGGAGG	TTGAAGCCAGGCATGCTGAT
<b>Hsa-circ-0008015</b>	TCCATCATGTACACAGGAGCAC	TGGTACCGATTGCGACCAGTG
<b>Hsa-circ-0009043</b>	GGAGAGCATCCGCAAACATTC	TAGTCGACACTGCTTCAGCTC
<b>Hsa-circ-0009161</b>	TCGCAATCGGTACCAAAGGT	CCGATCTGGGAAAGCTGTGAT
<b>Hsa-circ-0039943</b>	AGGAGGTGGCTTATGAAAGTGT	GCAGCAAGGCCTAATTCCAC
<b>Hsa-circ-0075650</b>	ACTTTGGACGAGAGCTGCAA	CACACCTTGAGCAGAAAGACC
<b>EXOC6B</b>	TCCTGCGAGAGATCGAGAGC	CTTCTCCATGAAACGTCCATGT
<b>U6</b>	CTCGCTTCGGCAGCACATATACT	ACGCTTCACGAATTTGCGTGTC

**Supplemental Table 2. Hsa-circ-0001030 expression and clinicopathological parameters**

<b>Variables</b>	<b>Expression</b>		<b>Total</b>	<b>P value</b>
	<b>Low</b>	<b>High</b>		
<b>Sex</b>				0.156
Male	38	26	64	
Female	10	14	24	
<b>Age (year)</b>				0.83
≤ 61	28	22	50	
> 61	20	18	38	
<b>TNM stage</b>				0.002
I / II	36	17	53	
III /IV	12	23	35	
<b>Grade</b>				0.04
I	11	18	29	
II/III	37	22	59	



**Supplementary Figure 1.** Hsa-circ-0001030 inhibits TSCC growth and pulmonary metastasis *in vivo*. (A) Quantitative analysis of bioluminescent radiance intensity in each group of tumor-bearing mice, showing reduced signal intensity in the hsa-circ-0001030 overexpression group compared with the vector control group; (B) Representative hematoxylin–eosin (HE) staining images of lung sections from each group, demonstrating fewer and smaller metastatic nodules in mice overexpressing hsa-circ-0001030.



**Supplementary Figure 2.** Hsa-circ-0001030 directly binds to PKM2 and regulates glycolytic activity in TSCC cells. (A and B) Specific binding of biotin-labeled probes to hsa-circ-0001030 was validated by qRT-PCR, confirming probe specificity; (C and D) RNA immunoprecipitation (RIP) analysis showing significant enrichment of hsa-circ-0001030 in samples immunoprecipitated with anti-PKM2 antibody compared with IgG control; (E) Gene Set Enrichment Analysis (GSEA) of transcriptomic profiles revealing downregulation of the glycolytic pathway in cells overexpressing

hsa-circ-0001030 compared with controls; (F) Gene Ontology (GO) enrichment analysis of differentially expressed genes between the hsa-circ-0001030 overexpression group and the control group, indicating that hsa-circ-0001030 modulates cellular metabolic processes; (G) Enzymatic activity assay of PKM2 among Cal27P, Cal27R, Tca8113P, and Tca8113R cells, showing elevated PKM2 activity in cisplatin-resistant sublines; (H and I) PKM2 activity assays demonstrating that hsa-circ-0001030 overexpression reduces PKM2 enzymatic activity in both parental and resistant TSCC cells; (J) Representative Western blot analysis of PKM2 oligomeric status in Cal27 and Cal27R cells with or without *hsa-circ-0001030* overexpression. Cell lysates were treated with 0.025% glutaraldehyde for cross-linking (+) or left untreated (-) prior to SDS-PAGE. The high-molecular-weight bands (~232 kDa) represent the tetrameric form of PKM2, whereas the 58 kDa bands correspond to monomeric PKM2; (K and L) Glucose consumption assays showing that hsa-circ-0001030 overexpression decreases glucose uptake in TSCC cells; (M and N) Lactate production assays demonstrating that hsa-circ-0001030 overexpression significantly lowers lactate output in TSCC cells; (O and P) Quantitative analysis of Transwell assays confirming that hsa-circ-0001030 overexpression suppresses the migration and invasion abilities of TSCC cells.